Hillstream BioPharma Announces Acceptance of Abstract at AACR 2023 Annual Meeting Highlighting HSB-510 as Novel Bi-functional Inhibitor for Solid Tumors & Leukemias
February 08 2023 - 7:11AM
Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the
"Company"), a biotechnology company developing therapeutic
candidates targeting drug resistant and devastating cancers using
ferroptosis, an emerging new anti-cancer mechanism resulting in
iron mediated cell death, and immuno-oncology targeted novel
biologics, today announced that an abstract highlighting the
progress of the Quatramer-based dual-targeted PI3-Kδ/HDAC6
inhibitor, HSB-510, and navitoclax (BCL-XL/BCL-2 inhibitor) has
been scheduled for presentation in a Poster Session at the 2023
American Association for Cancer Research (AACR) Annual Meeting in
Orlando, Florida and will be published in the online Proceedings of
the AACR.
The complete title: Co-loading of a novel PI3-Kδ/HDAC6 dual
inhibitor and navitoclax into Quatramer biodegradable polymeric
nanoparticles synergistically inhibit growth of ER+ breast
cancer.
Session Category: Experimental and
Molecular TherapeuticsSession Title: Drug
Delivery SystemsSession Date and Time: Monday
April 17, 2023 1:30 PM - 5:00
PMLocation: Section 15Poster Board
Number: 21Abstract Presentation
Number: 2718
The abstract will be published in the online Proceedings of AACR
supplement prior to the meeting on Friday March 31, 2023.
HSB-510 is a first-in-class isoform specific PI3-Kδ/HDAC6 dual
inhibitor encapsulated in the Company’s Quatramer-based
formulation. Preclinical studies have demonstrated that treating
TNBC cells with HSB-510 is associated with substantial down
regulation of the growth of TNBC cells both in vitro as well as in
TNBC syngeneic mouse model. Furthermore, the results also indicated
that treatment of TNBC cells with HSB-510 significantly inhibited
MYC levels. These findings indicated that dual inhibitor HSB-510 is
an effective agent targeting MYC and can be developed as effective
therapy for multiple MYC-dependent tumor indications.
About HSB-510HSB-510 is a novel highly targeted
bifunctional inhibitor encapsulated in Quatramer with single digit
nanomolar IC50 against PI3-Kδ and HDAC6, which is also known to
downregulate MYC, a highly pursued and yet undruggable cancer
target. The Quatramer platform achieves optimal tumor targeting and
bioavailability of the highly potent targeted small molecule.
Through a Cooperative Research and Development Agreement with the
National Center for Advancing Translational Sciences (NCATS), part
of the NIH, novel dual PI3-Kδ/HDAC6 inhibitors and a lead compound
showed good anti-proliferative activity against multiple cancer
cell lines. HSB-510 obtained ideal pharmacokinetic properties in
the Company’s proprietary Quatramer, while maintaining specific
PI3Kδ/HDAC6 specificity. The Company intends to continue a
collaborative effort with NCATS and expects to conduct IND-enabling
studies for HSB-510 in 2023.
About Hillstream BioPharma Inc.Hillstream
BioPharma, Inc. is a biotechnology company developing therapeutic
candidates targeting drug resistant and devastating cancers using
ferroptosis, an emerging new anti-cancer mechanism resulting in
iron mediated cell death, and immuno-oncology targeted novel
biologics. The Company’s most advanced candidate, HSB-1216,
expected to enter clinical trials in 2023, targets ferroptosis, an
emerging new anti-cancer mechanism resulting in iron mediated cell
death (IMCD) of drug resistant cancers. The Company’s emerging
immuno-oncology pipeline is led by the HSB-1940 Quatrabody™, an
anti-PD-1 novel biologic coated onto Quatramers, expected to enter
the clinic in 2024.
Hillstream’s Quatramer™ proprietary tumor targeting platform
extends duration of action and minimizes off-target toxicity for
biologics, mRNA, peptides, small molecules and other modalities in
the tumor microenvironment. Quatrabody conjugates novel biologics
developed against undruggable epitopes of validated immuno-oncology
targets, including PD-1, HER2, PDL-1, TROP2 and now MUC1-C, with
greater binding affinity than approved therapies. For more
information, please visit: www.hillstreambio.com.
Forward Looking StatementsCertain statements in
this press release are forward-looking within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
may be identified using words such as “anticipate,” “believe,”
“forecast,” “estimated” and “intend” or other similar terms or
expressions that concern Hillstream’s expectations, strategy, plans
or intentions. These forward-looking statements are based on
Hillstream’s current expectations and actual results could differ
materially. There are several factors that could cause actual
events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not
limited to, clinical trials involve a lengthy and expensive process
with an uncertain outcome, and results of earlier studies and
trials may not be predictive of future trial results; our clinical
trials may be suspended or discontinued due to unexpected side
effects or other safety risks that could preclude approval of our
product candidates; risks related to business interruptions,
including the outbreak of COVID-19 coronavirus, which could
seriously harm our financial condition and increase our costs and
expenses; dependence on key personnel; substantial competition;
uncertainties of patent protection and litigation; dependence upon
third parties; and risks related to failure to obtain FDA
clearances or approvals and noncompliance with FDA regulations.
Investors should read the risk factors set forth in our Form 10-K
for the year ended December 31, 2021 and our periodic reports filed
with the Securities and Exchange Commission. While the list of
factors presented here is considered representative, no such list
should be considered to be a complete statement of all potential
risks and uncertainties. Unlisted factors may present significant
additional obstacles to the realization of forward-looking
statements. Forward-looking statements included herein are made as
of the date hereof, and Hillstream does not undertake any
obligation to update publicly such statements to reflect subsequent
events or circumstances.
Investor Relations
Contact:Email: investorrelations@hillstreambio.comwww.hillstreambio.com
Source: Hillstream BioPharma Inc.
Hillstream BioPharma (NASDAQ:HILS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hillstream BioPharma (NASDAQ:HILS)
Historical Stock Chart
From Apr 2023 to Apr 2024